Rare diseases targeted by PTX could be company making. PTX 100...

Rare diseases targeted by PTX could be company making. PTX 100 has the potential imo to boost the market cap of PTX 10 to 20 times the current valuation. Recent presentation highlighted the high market valuation of those companies in the rare disease space. We should see some clinical trial of PTX100 in the rare disease space in late 2018. The stock price will most likely rerate well before any PTX 100 trial imo.
In the meantime PTX 200 in the AML space will also be a stock price driver. The chemo combo with PTX 200 for resistant/ relapse AML patients is something that is needed and will be followed by big pharma.